KR101634138B1 - 암 치료 방법 및 조성물 - Google Patents

암 치료 방법 및 조성물 Download PDF

Info

Publication number
KR101634138B1
KR101634138B1 KR1020107024132A KR20107024132A KR101634138B1 KR 101634138 B1 KR101634138 B1 KR 101634138B1 KR 1020107024132 A KR1020107024132 A KR 1020107024132A KR 20107024132 A KR20107024132 A KR 20107024132A KR 101634138 B1 KR101634138 B1 KR 101634138B1
Authority
KR
South Korea
Prior art keywords
cancer
cisplatin
treatment
sodium
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107024132A
Other languages
English (en)
Korean (ko)
Other versions
KR20110009664A (ko
Inventor
안젤리카 부르거
한스 헨드릭스
베르나르도 라데마케르
Original Assignee
코미녹스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코미녹스 인코포레이티드 filed Critical 코미녹스 인코포레이티드
Publication of KR20110009664A publication Critical patent/KR20110009664A/ko
Application granted granted Critical
Publication of KR101634138B1 publication Critical patent/KR101634138B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020107024132A 2008-03-27 2009-03-24 암 치료 방법 및 조성물 Expired - Fee Related KR101634138B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3998708P 2008-03-27 2008-03-27
US61/039,987 2008-03-27
US12/408,864 2009-03-23
US12/408,864 US20090246291A1 (en) 2008-03-27 2009-03-23 Method and compositions for treatment of cancer

Publications (2)

Publication Number Publication Date
KR20110009664A KR20110009664A (ko) 2011-01-28
KR101634138B1 true KR101634138B1 (ko) 2016-06-28

Family

ID=41114644

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107024132A Expired - Fee Related KR101634138B1 (ko) 2008-03-27 2009-03-24 암 치료 방법 및 조성물

Country Status (20)

Country Link
US (2) US20090246291A1 (https=)
EP (1) EP2268292B1 (https=)
JP (2) JP5543956B2 (https=)
KR (1) KR101634138B1 (https=)
CN (2) CN104997808A (https=)
AU (1) AU2009228378B2 (https=)
BR (1) BRPI0909164A2 (https=)
CA (1) CA2719766C (https=)
CY (1) CY1120536T1 (https=)
DK (1) DK2268292T3 (https=)
ES (1) ES2656762T3 (https=)
HU (1) HUE036609T2 (https=)
LT (1) LT2268292T (https=)
MX (1) MX2010010621A (https=)
PL (1) PL2268292T3 (https=)
PT (1) PT2268292T (https=)
RU (1) RU2508116C2 (https=)
SI (1) SI2268292T1 (https=)
WO (1) WO2009120697A2 (https=)
ZA (1) ZA201006988B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
PT2475362T (pt) * 2009-09-10 2019-05-27 Kominox Inc Terapia especifica para celulas estaminais cancerigenas e para 0 cancro resistente a medicamentos
US8795738B2 (en) * 2009-11-12 2014-08-05 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CN103153303A (zh) * 2010-07-18 2013-06-12 尼基制药公司 使用钌络合物的联合疗法
ES2718637T3 (es) * 2010-08-24 2019-07-03 Gtx Inc Compuestos para el tratamiento del cáncer
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
CN103826645A (zh) * 2011-05-12 2014-05-28 得克萨斯系统大学评议会 砷在癌症治疗保护中的用途
US8834938B2 (en) 2011-05-18 2014-09-16 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
KR101309844B1 (ko) 2013-03-15 2013-09-23 박상채 항암 활성 증진용 한약재 및 이의 제조방법
WO2014152330A1 (en) * 2013-03-15 2014-09-25 Stc.Unm Arsenic-based treatment of cancers and inflammatory disorders
MX372671B (es) * 2013-07-19 2020-04-23 Onyx Therapeutics Inc Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
ES2964979T3 (es) 2016-12-01 2024-04-10 Eupharma Pty Ltd Composiciones de arsénico
AU2019239671B2 (en) 2018-03-22 2025-02-27 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture
CN116236505A (zh) * 2023-03-15 2023-06-09 上海市第四人民医院 三氧化二砷在制备肺神经内分泌癌治疗药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519366A (ja) * 1997-10-15 2001-10-23 ポーラクス バイオファーマシュティカルズ，インコーポレーテッド ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法
IL136051A0 (en) * 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
EP1496918B1 (en) * 2002-04-10 2023-02-08 Komipharm International Co., Ltd. Use of sodium meta-arsenite for the treatment of tumours
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8097237B2 (en) * 2005-08-23 2012-01-17 Stc.Unm Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
US7867492B2 (en) * 2007-10-12 2011-01-11 The John Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies

Also Published As

Publication number Publication date
HUE036609T2 (hu) 2018-07-30
AU2009228378A1 (en) 2009-10-01
JP5543956B2 (ja) 2014-07-09
WO2009120697A3 (en) 2010-02-18
US20090246291A1 (en) 2009-10-01
MX2010010621A (es) 2011-04-05
ES2656762T3 (es) 2018-02-28
WO2009120697A2 (en) 2009-10-01
CN104997808A (zh) 2015-10-28
EP2268292A2 (en) 2011-01-05
CY1120536T1 (el) 2019-07-10
CA2719766C (en) 2017-10-31
SI2268292T1 (en) 2018-03-30
CA2719766A1 (en) 2009-10-01
KR20110009664A (ko) 2011-01-28
EP2268292A4 (en) 2011-05-11
PL2268292T3 (pl) 2018-06-29
LT2268292T (lt) 2018-03-26
AU2009228378B2 (en) 2014-07-17
US20180055812A1 (en) 2018-03-01
RU2010143893A (ru) 2012-05-10
RU2508116C2 (ru) 2014-02-27
WO2009120697A4 (en) 2010-04-15
CN102046187A (zh) 2011-05-04
PT2268292T (pt) 2018-02-19
DK2268292T3 (en) 2018-03-12
JP2011515481A (ja) 2011-05-19
ZA201006988B (en) 2012-05-30
JP2014101387A (ja) 2014-06-05
EP2268292B1 (en) 2017-12-27
BRPI0909164A2 (pt) 2016-06-21

Similar Documents

Publication Publication Date Title
KR101634138B1 (ko) 암 치료 방법 및 조성물
EP1383490B1 (en) Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases
JP2006503919A5 (https=)
RU2391101C2 (ru) Комбинированное применение эктеинасцидина-743 и содержащих платину противоопухолевых соединений
KR20230169462A (ko) Liv1-adc와 체크포인트 억제제를 사용한 병용 요법
EP2049121B1 (en) Compositions for promoting activity of anti-cancer therapies
Cheng et al. Chronic oral etoposide and tamoxifen in the treatment of far‐advanced hepatocellular carcinoma
MXPA04010166A (es) Politerapia para el tratamiento de cancer.
JP2003512301A (ja) アロマターゼ阻害剤と更なる生理活性化合物とを含む併用治療法
CA2468839A1 (en) Methods of treating cancer using an fpt inhibitor and anti neoplastic agents
US20250186438A1 (en) Treatment of clear cell renal cell carcinoma
EP1651227B1 (en) Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof
US6593303B1 (en) Anti-tumor synergetic composition
Sharma et al. New and potential therapies for the treatment of Breast Cancer: An update for oncologists
HK1152250B (en) Method and compositions for treatment of cancer
HK1152250A (en) Method and compositions for treatment of cancer
EP4506015A1 (en) Combination of a mps1 inhibitor and an antibody drug conjugate
CN120420332A (zh) 一种含mTOR抑制剂的组合物及其用途
Ramirez et al. Verapamil‐reversing concentrations induce blood flow changes that could counteract in vivo the MDR‐1‐modulating effects
Chen et al. A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study
Tolcher et al. 403 POSTER Clinical responses in highly refractory solid tumor patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care chemotherapy regimens: preliminary report from a multi-institutional phase-1b clinical trial
HK1060843B (en) Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases
AU2007201079A1 (en) Methods of treating cancer using an FPT inhibitor and antineoplastic agents

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A17-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190613

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

FPAY Annual fee payment

Payment date: 20200612

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20210616

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20220614

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250623

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250623

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250623